Skip to main content
. Author manuscript; available in PMC: 2019 Nov 11.
Published in final edited form as: Mol Cancer Res. 2018 May 21;16(9):1348–1360. doi: 10.1158/1541-7786.MCR-17-0634

Fig. 7. Nanoparticle-delivered miR-489 inhibits tumor growth and sensitized cells against doxorubicin in vivo.

Fig. 7.

A. miR-489 inhibits tumor growth and sensitized cells against doxorubicin in xenograft animals. After the tumors were palpable, the animals were randomly assigned into four groups (n=5 per group). All animals were injected with miR-489 or control encapsulated in nanoparticle every third day. The treatment starting day was referred to as ‘Day zero’ in the figure. B. IHC analysis revealed reduced expression of LAPTM4B and Ki67 in tumors treated with miR-489 encapsulated nanoparticles. C. Quantification of Ki-67 positive cells in tumors of all four groups. D. Western blot analysis of tumors revealed down regulation of ULK1, LAPTM4B and autophagy inhibition by miR-489. GAPDH was used as a loading control. E. miR-489 and LAPTM4B expression was measured in breast tissues form breast cancer patients (n=14) using qPCR. F. Correlation of miR-489 and its potential target gene expression in primary breast cancers. The linear dependence between miR489 and its potential target genes expression was evaluated by Pearson analysis of a published breast cancer data set (38). G. miR-489 expression predict overall survival of breast cancer patients with 8q22 gain/amplified tumors. Patient survival was estimated using the Kaplan-Meier method and compared with log-rank tests. The Y axis represents the probability of overall survival. *, p < 0.05; **, p < 0.01; ***, p < 0.001.